/PRNewswire/ Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients it serves, will inaugurate its new Global research.
Wide range of research across tumor types underscores Servier s commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3.
/PRNewswire/ Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and.
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based